'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature
- PMID: 18404411
- DOI: 10.1007/s10545-008-0832-y
'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature
Abstract
Gaucher disease is a lysosomal storage disorder, which is classically divided into three types. Type I Gaucher disease is differentiated from types II and III disease by the absence of nervous system involvement. However, an increasing number of reports has emerged on neurological manifestations in patients with type I Gaucher disease. Whether a strict division in three different phenotypes is still valid has been the subject of debate. The main objective of this study was to provide scientific arguments whether a distinction between type I (non-neuronopathic) and types II and III (neuronopathic) Gaucher disease should be maintained. We investigated retrospectively a large Dutch cohort of type I Gaucher disease patients for the prevalence of neurological manifestations and provide an overview of the literature on this topic. A diagnosis of a neurological disease was made 34 times in 75 patients. Forty-five patients reported at least one neurological symptom during the median follow-up time of 11 years. The literature search revealed 86 studies in which type I Gaucher disease patients or carriers of a glucocerebrosidase mutation were described with a neurological disease or a condition which is known to be associated with neurological disease. In conclusion, the term non-neuronopathic Gaucher disease does not seem to be an appropriate characterization of type I Gaucher disease. However, the neurological signs and symptoms in type I Gaucher disease are of a totally different kind from and, in the majority of cases, of much less severity than the signs and symptoms associated with types II and III disease Therefore, type I disease should be classified as a separate phenotype.
Similar articles
-
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240. Health Technol Assess. 2006. PMID: 16796930
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Neurological symptoms in adults with Gaucher disease: a systematic review.J Neurol. 2024 Jul;271(7):3897-3907. doi: 10.1007/s00415-024-12439-5. Epub 2024 May 21. J Neurol. 2024. PMID: 38771384 Free PMC article.
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
Cited by
-
Chronic pain in Gaucher disease: skeletal or neuropathic origin?Orphanet J Rare Dis. 2017 Aug 31;12(1):148. doi: 10.1186/s13023-017-0700-7. Orphanet J Rare Dis. 2017. PMID: 28859662 Free PMC article.
-
Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease.Orphanet J Rare Dis. 2014 Apr 14;9:51. doi: 10.1186/1750-1172-9-51. Orphanet J Rare Dis. 2014. PMID: 24731506 Free PMC article.
-
Gaucher disease: Biochemical and molecular findings in 141 patients diagnosed in Greece.Mol Genet Metab Rep. 2020 Jun 7;24:100614. doi: 10.1016/j.ymgmr.2020.100614. eCollection 2020 Sep. Mol Genet Metab Rep. 2020. PMID: 32547927 Free PMC article.
-
Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes.Haematologica. 2012 Dec;97(12):1850-4. doi: 10.3324/haematol.2011.059071. Epub 2012 Jul 6. Haematologica. 2012. PMID: 22773601 Free PMC article.
-
Healthcare resource utilization and cost of care for Gaucher patients in Iran.J Diabetes Metab Disord. 2019 Apr 9;18(1):127-132. doi: 10.1007/s40200-019-00399-x. eCollection 2019 Jun. J Diabetes Metab Disord. 2019. PMID: 31275883 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical